FDA 483 - DePuy Orthopaedics, Inc. - January 22, 2008

This FDA 483 observation identifies significant deficiencies in design validation conducted by Depuy, specifically concerning their Acalain Total Elbow System. While inspection dates were not provided, the primary issue found was that the company's design validation testing failed to adequately simulate the full range of clinical performance requirements for the device. Crucially, testing did not simulate device performance while articulating through a specific critical range, which could potentially lead to device failure during use. This indicates that the validation process did not thoroughly ensure the device's conformity to defined user and patient needs or its intended uses under all anticipated clinical conditions. This observation highlights a non-conformance with medical device quality system requirements, particularly those governing design controls and the validation necessary to confirm a device's safety and effectiveness. To address this, Depuy must implement corrective actions, including enhancing its design validation protocols to encompass comprehensive testing that accurately simulates the full spectrum of real-world clinical performance for the Acalain Total Elbow System, thereby ensuring the device's reliability and compliance with regulatory standards.